Amneal Pharmaceuticals In... (AMRX)
Amneal Pharmaceuticals Statistics
Share Statistics
Amneal Pharmaceuticals has 465.5M shares outstanding. The number of shares has increased by 50.82% in one year.
| Shares Outstanding | 465.5M |
| Shares Change (YoY) | 50.82% |
| Shares Change (QoQ) | 0.77% |
| Owned by Institutions (%) | 40.67% |
| Shares Floating | 157.87M |
| Failed to Deliver (FTD) Shares | 1 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 4.43M, so 1.41% of the outstanding shares have been sold short.
| Short Interest | 4.43M |
| Short % of Shares Out | 1.41% |
| Short % of Float | 2.2% |
| Short Ratio (days to cover) | 2.69 |
Valuation Ratios
The PE ratio is -20.94 and the forward PE ratio is 9.22. Amneal Pharmaceuticals's PEG ratio is 1.
| PE Ratio | -20.94 |
| Forward PE | 9.22 |
| PS Ratio | 0.88 |
| Forward PS | 1 |
| PB Ratio | -22.4 |
| P/FCF Ratio | 10.06 |
| PEG Ratio | 1 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Amneal Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.41, with a Debt / Equity ratio of -3.03.
| Current Ratio | 1.41 |
| Quick Ratio | 0.86 |
| Debt / Equity | -3.03 |
| Debt / EBITDA | 0.75 |
| Debt / FCF | 1.36 |
| Interest Coverage | 0.96 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $336.62K |
| Profits Per Employee | $-14.08K |
| Employee Count | 8,300 |
| Asset Turnover | 0.8 |
| Inventory Turnover | 2.9 |
Taxes
| Income Tax | 18.86M |
| Effective Tax Rate | -34.29% |
Stock Price Statistics
The stock price has increased by 37.69% in the last 52 weeks. The beta is 1.07, so Amneal Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 1.07 |
| 52-Week Price Change | 37.69% |
| 50-Day Moving Average | 8.15 |
| 200-Day Moving Average | 8.14 |
| Relative Strength Index (RSI) | 40.88 |
| Average Volume (20 Days) | 1.75M |
Income Statement
In the last 12 months, Amneal Pharmaceuticals had revenue of 2.79B and earned -116.89M in profits. Earnings per share was -0.38.
| Revenue | 2.79B |
| Gross Profit | 1.02B |
| Operating Income | 249.33M |
| Net Income | -116.89M |
| EBITDA | 439.77M |
| EBIT | 203.58M |
| Earnings Per Share (EPS) | -0.38 |
Balance Sheet
The company has 110.55M in cash and 331.35M in debt, giving a net cash position of -220.8M.
| Cash & Cash Equivalents | 110.55M |
| Total Debt | 331.35M |
| Net Cash | -220.8M |
| Retained Earnings | -607.06M |
| Total Assets | 3.5B |
| Working Capital | 458.04M |
Cash Flow
In the last 12 months, operating cash flow was 295.1M and capital expenditures -51.92M, giving a free cash flow of 243.18M.
| Operating Cash Flow | 295.1M |
| Capital Expenditures | -51.92M |
| Free Cash Flow | 243.18M |
| FCF Per Share | 0.79 |
Margins
Gross margin is 36.52%, with operating and profit margins of 8.92% and -4.18%.
| Gross Margin | 36.52% |
| Operating Margin | 8.92% |
| Pretax Margin | -1.97% |
| Profit Margin | -4.18% |
| EBITDA Margin | 15.74% |
| EBIT Margin | 8.92% |
| FCF Margin | 8.7% |
Dividends & Yields
AMRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for AMRX is $11.5, which is 55.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $11.5 |
| Price Target Difference | 55.8% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | 1.48 |
| Piotroski F-Score | 5 |